Ototoxic and nephrotoxic drugs in neonatal intensive care units: results of a Spanish and Italian survey
- PMID: 38492032
- DOI: 10.1007/s00431-024-05467-w
Ototoxic and nephrotoxic drugs in neonatal intensive care units: results of a Spanish and Italian survey
Abstract
Neonates face heightened susceptibility to drug toxicity, often exposed to off-label medications with dosages extrapolated from adult or pediatric studies. Premature infants in Neonatal Intensive Care Units (NICUs) are particularly at risk due to underdeveloped pharmacokinetics and exposure to multiple drugs. The study aimed to survey commonly used medications with a higher risk of ototoxicity and nephrotoxicity in Spanish and Italian neonatal units. A prospective cross-sectional study was conducted in Italian and Spanish neonatal units using a web-based survey with 43 questions. A modified Delphi method involved experts refining the survey through online consensus. Ethical approval was obtained, and responses were collected from January to July 2023. The survey covered various aspects, including drug-related ototoxic and nephrotoxic management, hearing screening, and therapeutic drug monitoring. Responses from 131 participants (35.9% from Spain and 64.1% from Italy) revealed awareness of drug toxicity risks. Varied practices were observed in hearing screening protocols, and a high prevalence of ototoxic and nephrotoxic drug use, including aminoglycosides (100%), vancomycin (70.2%), loop diuretics (63.4%), and ibuprofen (62.6%). Discrepancies existed in guideline availability and adherence, with differences between Italy and Spain in therapeutic drug monitoring practices.
Conclusions: The study underscores the need for clinical guidelines and uniform practices in managing ototoxic and nephrotoxic drugs in neonatal units. Awareness is high, but inconsistencies in practices indicate a necessity for standardization, including the implementation of therapeutic drug monitoring and the involvement of clinical pharmacologists. Addressing these issues is crucial for optimizing neonatal care in Southern Europe.
What is known: • Neonates in intensive care face a high risk of nephrotoxicity and ototoxicity from drugs like aminoglycosides, vancomycin, loop diuretics, and ibuprofen. • Therapeutic drug monitoring is key for managing these risks, optimizing dosing for efficacy and minimizing side effects.
What is new: • NICUs in Spain and Italy show high drug toxicity awareness but differ in ototoxic/nephrotoxic drug management. • Urgent need for standard guidelines and practices to address nephrotoxic risks from aminoglycosides, vancomycin, loop diuretics, and ibuprofen.
Keywords: Acute kidney injury; Hearing impairment; Neonates; Nephrotoxicity; Ototoxicity; Pharmacodynamics.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Furosemide use in Italian neonatal intensive care units: a national survey.Ital J Pediatr. 2020 Jun 22;46(1):86. doi: 10.1186/s13052-020-00851-2. Ital J Pediatr. 2020. PMID: 32571386 Free PMC article.
-
Extended-interval aminoglycoside administration for children: a meta-analysis.Pediatrics. 2004 Jul;114(1):e111-8. doi: 10.1542/peds.114.1.e111. Pediatrics. 2004. PMID: 15231982
-
Vancomycin is commonly under-dosed in critically ill children and neonates.Br J Clin Pharmacol. 2019 Nov;85(11):2591-2598. doi: 10.1111/bcp.14084. Epub 2019 Aug 30. Br J Clin Pharmacol. 2019. PMID: 31378957 Free PMC article.
-
Drug-induced acute kidney injury in neonates.Curr Opin Pediatr. 2016 Apr;28(2):180-7. doi: 10.1097/MOP.0000000000000311. Curr Opin Pediatr. 2016. PMID: 26735892 Free PMC article. Review.
-
Ototoxic Drug Exposure and Hearing Loss in Neonates: A Scoping Review.Am J Audiol. 2024 Dec 2;33(4):1356-1377. doi: 10.1044/2024_AJA-24-00065. Epub 2024 Sep 23. Am J Audiol. 2024. PMID: 39312737
Cited by
-
Newborn Hearing Screening-Polish Experience: A Narrative Review.J Clin Med. 2025 Apr 17;14(8):2789. doi: 10.3390/jcm14082789. J Clin Med. 2025. PMID: 40283619 Free PMC article. Review.
References
-
- Schrier L, Hadjipanayis A, Stiris T, Ross-Russell RI, Valiulis A, Turner MA, Zhao W, De Cock P, de Wildt SN, Allegaert K, van den Anker J (2020) Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr 179:839–847 - PubMed - DOI
-
- Allegaert K, Van De Velde M, van den Anker J (2014) Neonatal clinical pharmacology. Pediatr Anesthesia 24:30–38 - DOI
MeSH terms
LinkOut - more resources
Full Text Sources